ERBB2 and breast carcinoma: According to a phase III clinical trial (NCT02278120),ribociclib + letrozole treatment improved progression-free survival for premenopausal women bearing HR + and HER2 − progressive breast carcinoma, while exhibited a tolerable safety profile [79].